|
|
Post by sla55 on Nov 1, 2016 8:06:12 GMT -5
MannKind Corporation to Hold 2016 Third Quarter Financial Results Conference Call on November 9, 2016 VALENCIA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 third quarter financial results on Wednesday, November 9, 2016 and its management will host a conference call and presentation webcast to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 9, 2016. Presenting from the Company will be its Chief Executive Officer, Matthew J. Pfeffer and other members of senior management. To view and listen to the webcast, visit MannKind's website at www.mannkindcorp.com and click on the "Q3 2016 MannKind Earnings Conference Call" link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 41477573. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4147 7573#. A replay will also be available on MannKind's website for 14 days. |
|
|
|
Post by peppy on Nov 1, 2016 8:07:35 GMT -5
thank you sla
|
|
|
|
Post by peppy on Nov 1, 2016 15:20:27 GMT -5
We have a week to wait to hear what MNKD is going to tell us.
Financing.
Afrezza.
Manufacturing/Distribution.
Sales.
Revenues.
Receivables.
Technosphere.
The plan.
|
|
|
|
Post by broncolife on Nov 1, 2016 16:42:30 GMT -5
Nov 9th, is a perfect date for RLS news as the results of all state marijuana initiatives will be known.
|
|
|
|
Post by bioexec25 on Nov 1, 2016 16:46:14 GMT -5
Nov 9th, is a perfect date for RLS news as the results of all state marijuana initiatives will be known. Now that's a different perspective. I like the way you think. |
|
|
|
Post by bioexec25 on Nov 1, 2016 16:53:36 GMT -5
We have a week to wait to hear what MNKD is going to tell us. Financing. Afrezza. Manufacturing/Distribution. Sales. Revenues. Receivables. Technosphere. The plan. Ugh so many topics for the call Peppy. ;-)). Like in school it was easier for me although didn't always practice to treat the final as just another exam because I've prepared steadily all semester (mnkd communicate more) instead of cramming. These comprehensive finals (ER calls with prior silence) are tough even for smart folks. |
|
|
|
Post by orlon on Nov 1, 2016 17:56:07 GMT -5
Peppy, you need to add 1: bankruptcy 2: reverse split 3: .43cent/shr price.
|
|
|
|
Post by peppy on Nov 1, 2016 19:13:02 GMT -5
with out a sanofi settlement, and a cash injection (rls?) I can am not smart enough to see a way out.
Interesting in that times have changed. Human beings couldn't see the behavior of glucose to food and insulin before.
With the Continuous glucose monitor the observable difference in glucose levels, less highs for less time. Less lows for less time.
The HgbA1c should be reflecting the more time in range.
If we get some money and the pediatric trials are done with continuous glucose monitors....
Amazing that such an effective meal time insulin is being crushed.
|
|
|
|
Post by nadathing on Nov 1, 2016 19:22:17 GMT -5
with out a sanofi settlement, and a cash injection (rls?) I can am not smart enough to see a way out. Interesting in that times have changed. Human beings couldn't see the behavior of glucose to food and insulin before. With the Continuous glucose monitor the observable difference in glucose levels, less highs for less time. Less lows for less time. The HgbA1c should be reflecting the more time in range. If we get some money and the pediatric trials are done with continuous glucose monitors.... Amazing that such an effective meal time insulin is being crushed. I'm of the opinion that the future of Afrezza is in treating juvenile diabetes and that Afrezza is a niche drug for T2's. Unfortunately, it may be too late for MNKD. Not enough money or time left. Will another company see the potential, pick up the ball and run with it? I don't hold out much hope, but it is all I have left. |
|
|
|
Post by peppy on Nov 1, 2016 19:35:31 GMT -5
with out a sanofi settlement, and a cash injection (rls?) I can am not smart enough to see a way out. Interesting in that times have changed. Human beings couldn't see the behavior of glucose to food and insulin before. With the Continuous glucose monitor the observable difference in glucose levels, less highs for less time. Less lows for less time. The HgbA1c should be reflecting the more time in range. If we get some money and the pediatric trials are done with continuous glucose monitors.... Amazing that such an effective meal time insulin is being crushed. I'm of the opinion that the future of Afrezza is in treating juvenile diabetes and that Afrezza is a niche drug for T2's. Unfortunately, it may be too late for MNKD. Not enough money or time left. Will another company see the potential, pick up the ball and run with it? I don't hold out much hope, but it is all I have left. Yes, nada. Teva is sounding really good to me again. They could take over the fast acting insulin market. |
|
|
|
Post by bradleysbest on Nov 4, 2016 8:49:06 GMT -5
Scripts suck, insurance is getting better, but will MNKD survive with out funding? I'm praying that MNKD has secured funding for 2017 to keep Afrezza alive.... Hopefully something is announced (positive) at the CC.
|
|
|
|
Post by dictatorsaurus on Nov 4, 2016 8:56:15 GMT -5
Scripts suck, insurance is getting better, but will MNKD survive with out funding? I'm praying that MNKD has secured funding for 2017 to keep Afrezza alive.... Hopefully something is announced (positive) at the CC. If financing is secured for 2017, what guarantee we have scripts will increase, let alone break even? They haven't laid out a plan (a successful one) that monitors progress with multiple contingency plans. The concern is not just because scripts are kinda low. They are extremely low. Basically nonexistent. |
|
|
|
Post by bradleysbest on Nov 4, 2016 8:59:15 GMT -5
There are no guarantees but MNKD can't survive on these script numbers! My hope is there is funding for DTC that will create a demand for Afrezza. The 1st 2 launches have not created that demand.
|
|
|
|
Post by zuegirdor on Nov 4, 2016 11:49:38 GMT -5
Scripts suck, insurance is getting better, but will MNKD survive with out funding? I'm praying that MNKD has secured funding for 2017 to keep Afrezza alive.... Hopefully something is announced (positive) at the CC. If financing is secured for 2017, what guarantee we have scripts will increase, let alone break even? They haven't laid out a plan (a successful one) that monitors progress with multiple contingency plans. The concern is not just because scripts are kinda low. They are extremely low. Basically nonexistent. While the total number of scripts and revenue is below what is needed to demonstrate Afrezza is a going concern, the "nonexistent" label oversimplifies and distracts from more quantitative analysis that is available. Perhaps now that the coverage situation is improving, Mannkind will be able to justify more reps in the field. Assuming the new reps work at same efficiency, doubling the number of reps will double the number of new scripts and revenue at double the cost. If production costs remain fixed per volume, this will more than double the profit(or reduce time to profitability). Increase reps according to the profitability prediction curve. At some point the reps can be let go = cost savings etc etc. Of course the forgoing assumes you have a superior product and virtuous market. |
|
|
|
Post by matt on Nov 4, 2016 12:20:19 GMT -5
If financing is secured for 2017, what guarantee we have scripts will increase, let alone break even? They haven't laid out a plan (a successful one) that monitors progress with multiple contingency plans. The concern is not just because scripts are kinda low. They are extremely low. Basically nonexistent. While the total number of scripts and revenue is below what is needed to demonstrate Afrezza is a going concern, the "nonexistent" label oversimplifies and distracts from more quantitative analysis that is available. Perhaps now that the coverage situation is improving, Mannkind will be able to justify more reps in the field. Assuming the new reps work at same efficiency, doubling the number of reps will double the number of new scripts and revenue at double the cost. If production costs remain fixed per volume, this will more than double the profit(or reduce time to profitability). Increase reps according to the profitability prediction curve. At some point the reps can be let go = cost savings etc etc. Of course the forgoing assumes you have a superior product and virtuous market. More salesmen doesn't address the other part of the equation and that is loss of refills. If you look at the data that Liane updates weekly, the refills this week were less than 50% of the total scripts 13 weeks ago (roughly a 90 day fill). Adding resources to increase new scripts only makes sense if Mannkind can hold onto them. When Sanofi dropped the partnership they cited the loss of 65% of patients between the original prescription and the refill date, and if Mannkind is somewhere above 50% loss of patients that implies there is a lot of work to be done with patient satisfaction. |
|
